NCT06393881

A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201

A Randomized, Open-label, Multiple-dose Crossover Phase 1 Clinical Trial to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics Characteristics After Oral Administration of UI059 and UIC202201 in Healthy Adult Volunteers

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: Korea United Pharm. Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

A randomized, open-label, multiple-dose crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers

Conditions

• Gastro-Intestinal Disorder

Interventions

Type	Name	Description
DRUG	UI059	take UI059 once a day for 7 days
DRUG	UIC202201	take UIC202201 once a day for 7 days

Timeline

• Start date: 2024-07-03
• Primary completion: 2024-09-14
• Completion: 2024-09-21
• First posted: 2024-05-01
• Last updated: 2024-05-01

Locations

1 site across 1 country: South Korea